Hims & Hers Health Faces a 15% Stock Swing on Its Weight-Loss Pivot
NEW YORK, May 9 —
Options traders are pricing a ~15% move in Hims & Hers Health around Q1 earnings — the first print that turns the weight-loss pivot from a narrative into actual numbers.
- Options market implying a ~15% swing in either direction at the Q1 print; analysts are split on beat vs. miss
- HIMS trades at 20.5x fwd P/E against $2.3bn TTM revenue — a multiple that assumes durable weight-loss growth
- Next catalyst: Q1 earnings imminent; watch weight-loss segment contribution as a share of total revenue vs. analyst consensus
What Actually Happened
Hims & Hers pivoted into compounded semaglutide as GLP-1 demand outpaced the supply of branded versions, and the stock held above $28 on that growth story. The valuation complicates the picture: at 20.5x fwd P/E, this multiple requires more than clean execution. It requires the FDA to leave the compounding window open. The FDA has already moved to restrict semaglutide compounding, which directly threatens the revenue line supporting that premium. Q1 is the first major print where weight-loss segment contribution shows up as actual revenue dollars, not modeled from early subscriber trends. That shift — from sign-up counts to booked revenue — is what makes this quarter binary.
The Catch
The bear case here is not a product problem or a marketing misstep. It is the FDA. A strong Q1 weight-loss print buys one more quarter; the next question is whether the compounding window stays open through Q2 and beyond. A stock at 20.5x forward earnings needs its core growth driver to be repeatable. Compounded semaglutide revenue is not — it depends on an FDA posture that has already shifted once and could shift again. "Mixed" analyst consensus is shorthand for one uncomfortable fact: nobody has conviction on what the agency does next. That uncertainty puts a wide band around any fair-value estimate for this stock.
Bottom Line
At $28.27, HIMS is a growth stock with a regulatory arbitrage trade embedded in the multiple. The Q1 print either validates the 20.5x fwd P/E or removes the case for it. Growth investors have a clean near-term trade if weight-loss revenue beats estimates. Value investors lack the regulatory visibility to size a position with confidence. One number decides this: weight-loss segment revenue as a share of Q1 total revenue, measured against analyst consensus.
For a full financial breakdown of Hims & Hers Health, generate a Basis Report at /stock/hims.
Basis Report does not hold positions in securities discussed. This is not investment advice.